604010-24-4

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 2,6-dimethyl-4-oxopiperidine-1-carboxylate (mixture of cisand trans-) is used as an intermediate in the synthesis of various pharmaceuticals for its versatile structural features and ability to serve as a building block in organic synthesis.
Used in Agrochemical Industry:
Tert-butyl 2,6-dimethyl-4-oxopiperidine-1-carboxylate (mixture of cisand trans-) is used as an intermediate in the synthesis of various agrochemicals, contributing to the development of new and effective compounds for agricultural applications.
Used in Organic Synthesis:
Tert-butyl 2,6-dimethyl-4-oxopiperidine-1-carboxylate (mixture of cisand trans-) is used as a reagent in the preparation of complex molecules, taking advantage of its structural features and versatility in organic synthesis.
Used in Drug Development:
Tert-butyl 2,6-dimethyl-4-oxopiperidine-1-carboxylate (mixture of cisand trans-) has potential applications in the development of new drug candidates, serving as a precursor for the creation of various functionalized piperidine derivatives with potential therapeutic properties.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1005397-62-5 2,6-dimethylpiperidin-4-one hydrochloride 
• 32941-09-6 1-benzyl-2,6-dimethylpiperidin-4-one 
• 45717-87-1 2,6-dimethylpiperidin-4-one 

Downstream Products

• 1005397-65-8 tert-butyl 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate 

Relevant academic research and scientific papers

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, R3, Rx, and n are as defined herein, and methods of making and using same.

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

TRPA1 MODULATORS

This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.